Menu
V

Valley Retina Institute, PA | McAllen, TX

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

APL-2
BI 764524
Vitrase
THR-687
KVD001
Pegcetacoplan
Triamcinolone Acetonide
RBM-007
AR-15512
EYE103

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Active trials

Phase 1/2 dose-escalation and randomized, controlled, masked expansion trial in adults with wet AMD undergoing active anti-VEGF treatment

Enrolling
Neovascular (Wet) Age-Related Macular Degeneration
Biological: 4D-150 IVT
Biological: Aflibercept IVT
Locations recently updated

This study is open to adults with diabetic retinopathy. People who have non-proliferative diabetic retinopathy of moderate or high severity can join...

Enrolling
Diabetic Retinopathy
Drug: BI 764524
Drug: Aflibercept (Eylea®) - US only

A study to evaluate the safety and efficacy of YUTIQ® 0.18 mg intravitreal implant for the management of chronic non-infectious posterior segment uve...

Active, not recruiting
Uveitis, Posterior
Drug: Fluocinolone Acetonide Intravitreal Implant 0.18 mg

OPL-0401-201 is a multicenter study to investigate the safety and efficacy of OPL-0401 in patients with diabetes mellitus (DM) with diabetic retinopa...

Active, not recruiting
Non-proliferative Diabetic Retinopathy
Proliferative Diabetic Retinopathy
Drug: Placebo
Drug: OPL-0401 Dose 1

The purpose of this clinical trial is to compare safety, tolerability, efficacy, and durability of two dose levels of suprachoroidal sustained-releas...

Active, not recruiting
Diabetic Macular Edema
Device: Semi-automated suprachoroidal illuminated microcatheter
Drug: Ozurdex® Ophthalmic Intravitreal Implant
Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trial sponsors

A
A
Bausch + Lomb logo
Boehringer Ingelheim logo
T
4
Aerie Pharmaceuticals logo
C
E
E